1481677-78-4
1481677-78-4 結(jié)構(gòu)式
基本信息
G9A和GLP抑制劑(UNC0642)
2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-異丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺
UNC0642
UNC 0642
UNC-0642
UNC-0642
UNC0642
UNC 0642
2-(4,4-difluoropiperidin-1-yl)-N-(1-isopropylpiperidin-4-yl)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-4-amine
2-(4,4-Difluoropiperidin-1-yl)-6-methoxy-N-[1-(propan-2-yl)piperidin-4-yl]-7-[3-(pyrrolidin-1-yl)propoxy]quinazolin-4-amine
2-(4,4-Difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinamine
4-Quinazolinamine, 2-(4,4-difluoro-1-piperidinyl)-6-methoxy-N-[1-(1-methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-
UNC0642, 2-(4,4-Difluoro-1-piperidinyl)-6-Methoxy-N-[1-(1-Methylethyl)-4-piperidinyl]-7-[3-(1-pyrrolidinyl)propoxy]-4-quinazolinaMine
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/02/08 | HY-13980 | 2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-異丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺 UNC0642 | 1481677-78-4 | 1 mg | 340元 |
| 2025/02/08 | HY-13980 | 2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-異丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺 UNC0642 | 1481677-78-4 | 5mg | 750元 |
| 2025/02/08 | HY-13980 | 2-(4,4-二氟-1-哌啶基)-6-甲氧基-N-[1-異丙基-4-哌啶基]-7-[3-(1-吡咯烷基)丙氧基]-4-喹唑啉胺 UNC0642 | 1481677-78-4 | 10mM * 1mLin DMSO | 902元 |
常見問題列表
IC50: <2.5 nM (G9a)
UNC0642 displays high in vitro and cellular potency, low cell toxicity, and excellent selectivity. UNC0642 is competitive with the peptide substrate and non-competitive with the cofactor SAM. The K i of UNC0642 is determined to be 3.7±1 nM. UNC0642 displays high in vitro potency for GLP (IC 50 < 2.5 nM), similar to G9a. UNC0642 is more than 300-fold selective for G9a and GLP over a broad range of kinases, GPCRs, transporters, and ion channels. UNC0642 exhibits high potency at reducing the H3K9me2 mark, low cell toxicity, and good separation of functional potency and cell toxicity in a number of cell lines. It reduces clonogenicity in PANC-1 cells, a pancreatic carcinoma cell line.
A single intraperitoneal (IP) injection (5 mg/kg) of UNC0642 results in a plasma C max (maximum concentration) of 947 ng/mL and an AUC (area under the curve) of 1265 hr*ng/mL.